Comment
doi: 10.1016/S1470-2045(08)70163-3.
Immunotherapeutic potential of oncolytic virotherapy
- PMID: 18598928
- DOI: 10.1016/S1470-2045(08)70163-3
Item in Clipboard
Comment
Immunotherapeutic potential of oncolytic virotherapy
Lancet Oncol.
2008 Jul.
No abstract available
Comment on
-
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.Lancet Oncol. 2008 Jun;9(6):533-42. doi: 10.1016/S1470-2045(08)70107-4. Epub 2008 May 19. Lancet Oncol. 2008. PMID: 18495536 Clinical Trial.
Similar articles
-
A smart move against cancer for vaccinia virus.Lancet Oncol. 2008 Jun;9(6):507-8. doi: 10.1016/S1470-2045(08)70136-0. Lancet Oncol. 2008. PMID: 18510983 No abstract available.
-
Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma.Nat Rev Clin Oncol. 2015 Aug;12(8):438. doi: 10.1038/nrclinonc.2015.106. Epub 2015 Jun 16. Nat Rev Clin Oncol. 2015. PMID: 26077044 No abstract available.
-
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.Lancet Oncol. 2008 Jun;9(6):533-42. doi: 10.1016/S1470-2045(08)70107-4. Epub 2008 May 19. Lancet Oncol. 2008. PMID: 18495536 Clinical Trial.
-
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.Cancer Immunol Immunother. 2017 Oct;66(10):1249-1264. doi: 10.1007/s00262-017-2025-8. Epub 2017 Jul 15. Cancer Immunol Immunother. 2017. PMID: 28712033 Free PMC article. Review.
-
Newcastle disease virus: a promising agent for tumour immunotherapy.Clin Exp Pharmacol Physiol. 2012 Aug;39(8):725-30. doi: 10.1111/j.1440-1681.2011.05662.x. Clin Exp Pharmacol Physiol. 2012. PMID: 22211810 Review.
Cited by
-
Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.Clin Cancer Res. 2009 Jul 1;15(13):4374-4381. doi: 10.1158/1078-0432.CCR-09-0334. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509134 Free PMC article.
-
Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses.Microb Biotechnol. 2012 Mar;5(2):251-9. doi: 10.1111/j.1751-7915.2011.00296.x. Epub 2011 Sep 19. Microb Biotechnol. 2012. PMID: 21923638 Free PMC article. Review.
-
Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Front Immunol. 2014 Feb 24;5:74. doi: 10.3389/fimmu.2014.00074. eCollection 2014. Front Immunol. 2014. PMID: 24605114 Free PMC article. Review.
-
Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses-Clearance and Biodistribution in Naïve and HSV-Preimmune Mice.Cancers (Basel). 2023 Aug 10;15(16):4042. doi: 10.3390/cancers15164042. Cancers (Basel). 2023. PMID: 37627072 Free PMC article.
-
Regulation of immunogenic cell death and potential applications in cancer therapy.Front Immunol. 2025 Mar 26;16:1571212. doi: 10.3389/fimmu.2025.1571212. eCollection 2025. Front Immunol. 2025. PMID: 40207233 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
